Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.09.2017 | short review | Ausgabe 3/2017

memo - Magazine of European Medical Oncology 3/2017

Chemotherapies and future directions in metastatic colorectal cancer

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 3/2017
Autor:
PhD PD Dr. Thomas Winder

Summary

Substantial progress has been achieved in the management of metastatic colorectal cancer (mCRC) over the last two decades. The overall survival has increased from 10 months to more than 30 months. These improvements are due to the integration of multiple cytotoxic agents and targeted therapies, as well as individualized treatment strategies using molecular and clinical factors. More specific, molecular characteristics such as RAS mutation status and clinical factors such as performance status, tumor burden, tumor-related symptoms and comorbidities are crucial in selecting treatment strategies. Here I review the landscape of cytotoxic chemotherapy for mCRC, regional chemotherapy strategies to accumulate cytotoxics within the tumor and reflect on future directions for treatment of mCRC.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2017

memo - Magazine of European Medical Oncology 3/2017 Zur Ausgabe